

documents, business management technical assistance may be obtained from: Glynnis Taylor, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Program Announcement 01038.

Centers for Disease Control and Prevention (CDC), 2920 Brandywine Road, Room 3000, Atlanta, GA 30341-4146, Telephone number: (770) 488-2752, Email address: gld1@cdc.gov.

For program technical assistance, contact: Amy DeGross, Program Services Branch, Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE., Mailstop K-57, Atlanta, GA 30341-3724, Telephone number: (770) 488-4248, Email address: asd1@cdc.gov.

Dated: May 22, 2001.

**Henry S. Cassell III,**

*Acting Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 01-13498 Filed 5-29-01; 8:45 am]

**BILLING CODE 4163-18-P**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee; Notice of Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

*Name of Committee:* Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee.

*General Function of the Committee:* To provide advice and recommendations to the agency on scientific disputes between the Center for Devices and Radiological Health and sponsors, applicants, and manufacturers.

*Date and Time:* The meeting will be held on June 4, 2001, 10:30 a.m. to 5 p.m.

*Location:* Corporate Bldg., conference room 20B, 9200 Corporate Blvd., Rockville, MD.

*Contact:* Les Weinstein, Center for Devices and Radiological Health (HFZ-5), Food and Drug Administration, 9200

Corporate Blvd., Rockville, MD 20850, 301-443-6220, ext. 119, FAX 301-827-2565, lsw@cdrh.fda.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572) in the Washington, DC area), code 10232. Please call the Information Line for up-to-date information on this meeting.

*Agenda:* The committee will discuss, make recommendations, and vote regarding a scientific dispute between the agency and Lifecore Biomedical, Inc., related to the approvability of a premarket approval application for Intergel, an adhesion prevention solution. Background information and questions for the committee will be available to the public on June 1, 2001, on the Internet at <http://www.fda.gov/cdrh/panelmtg.html>.

*Procedure:* Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by May 31, 2001. Oral presentations from the public will be scheduled between approximately 10:30 a.m. to 11 a.m. Near the end of the committee deliberations, a 30-minute open public session will be conducted for interested persons to address issues specific to the dispute before the committee. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before May 31, 2001, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

FDA regrets that it was unable to publish this notice 15 days prior to the June 4, 2001, Medical Devices Dispute Resolution Panel of the Medical Devices Advisory Committee meeting. Because the agency believes there is some urgency to bring this issue to public discussion and qualified members of the Medical Devices Dispute Resolution Panel of the Medical Devices Advisory committee were available at this time, the Commissioner of Food and Drugs concluded that it was in the public interest to hold this meeting even if there was not sufficient time for the customary 15-day public notice.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: May 24, 2001.

**Linda A. Suydam,**

*Senior Associate Commissioner.*

[FR Doc. 01-13639 Filed 5-25-01; 3:08 pm]

**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Proposed Collection; Comment Request; Leukemia and Other Hematological Diseases Among Cleanup Workers in Ukraine Following the Chernobyl Accident**

**SUMMARY:** In compliance with the requirement of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the National Cancer Institute, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.

**Proposed Collection**

*Title:* Leukemia and Other Hematological Diseases Among Cleanup Workers in Ukraine Following the Chernobyl Accident. *Type of Information Collection Request:* New. *Need and Use of Information Collection:* A case-control study will be conducted to investigate the risk of radiation-induced leukemia and other hematological diseases among Chernobyl cleanup workers in Ukraine. Cases and controls (or proxies) will be interviewed to provide details of their work during the Chernobyl clean-up operation. The interview responses combined with environmental measurements will permit individual bone marrow dose estimates to be calculated for each case and control. Dose estimates will be used to calculate the risk of leukemia and other hematological diseases associated with low-dose and low dose-rate radiation exposure. This information, which is essential for radiation protection, is currently not available and standards presently are based on information available only by extrapolation from high-dose, high dose-rate data on A-bomb survivors in Japan. *Frequency of Response:* One time only. *Affected Public:* Ukrainian Chernobyl clean-up workers. *Type of respondents:* Cases, controls, and proxies for deceased subject. *Estimated Number of Respondents:* 700. *Estimated Number of Responses per Respondent:* Variable, about 50. *Average Burden Hours Per Response:* 0.75 hour. *Estimated Total Annual Burden Hours Requested:* 400 hours (interviews to be conducted over 18-month period). There are no Capital Costs, Operating Costs, and/or Maintenance Costs to report.

**Request for Comments**

Written comments and/or suggestions from the public and affected agencies are invited on one or more of the following points: (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the National Cancer Institute, including whether the information will have practical utility; (2) evaluate the accuracy of the NCI's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) enhance the enhance the quality utility, and clarity of the information to be collected; (4) minimize the burden of the collection of information on those who are to respond, including the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology.

**FOR FURTHER INFORMATION CONTACT:** To request more information on the proposed project or to obtain a copy of the data collection plans and instruments, contact Dr. Terry L. Thomas, National Cancer Institute, EPS 7100, 6120 Executive Boulevard, Rockville, MD, 29892-7238, or call the non-toll-free number (301) 496-6600.

**Comments Due Date:** Comments regarding this information collection are best assured of having their full effect if received on or before July 30, 2001.

Dated: May 16, 2001.

**Reesa Nichols,**

*NCI Project Clearance Liaison.*

[FR Doc. 01-13484 Filed 5-29-01; 8:45 am]

**BILLING CODE 4140-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which

would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Improving DNA, RNA and Protein availability in Fixed Tissue.

**Date:** June 15, 2001.

**Time:** 8 a.m. to 2 p.m.

**Agenda:** To review and evaluate grant applications.

**Place:** National Cancer Institute, 6130 Executive Boulevard, Conference Room F, Rockville, MD 20852.

**Contact Person:** Gerald G. Lovinger, Scientific Review Administrator, Grants Review Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8101, Rockville, MD 20892-7405, 301/496-7987.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 23, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-13539 Filed 5-29-01; 8:45 am]

**BILLING CODE 4140-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 55b(c)(4) and 552(b)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel Research in State and Community Tobacco Control.

**Date:** June 17-18, 2001.

**Time:** 6:30 PM to 5 PM.

**Agenda:** To review and evaluate grant applications.

**Place:** Holiday Inn, 8120 Wisconsin Avenue, Bethesda, MD 20814.

**Contact Person:** C.M. Kerwin, Scientific Review Administrator, Special Review and Resources Branch, Division of Extramural Activities, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Room 8039, Rockville, MD 20892-7405, 301/496-7421.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: May 23, 2001.

**LaVerne Y. Stringfield,**

*Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 01-13540 Filed 5-29-01; 8:45 am]

**BILLING CODE 4140-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****National Institutes of Health****National Cancer Institute; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Spores in Skin Cancer.

**Date:** June 21-22, 2001.

**Time:** 8 a.m. to 6 p.m.